Prevalence and risk factors of metabolic syndrome among drug-naive psychotic patients

Fawzy, Nagy; Shabrawy, Amany El; Youssef, Amira M.

doi:10.4103/1110-1105.158118

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a comparison of the overall prevalence from this study to that obtained among psychiatric patients in Ghana shows a consistent rise in the prevalence of MetS among these patients over the years regardless of definition criteria (IDF = 23.6% versus 15.5%; WHO = 20.4% versus 13.5%; NCEP ATP III = 14.1% versus 11.5%) [ 22 , 23 ]. Furthermore, the MetS prevalence observed in this study was in agreement with a range of prior reports published regionally and worldwide, although there is a considerable variation in criteria and methodology among the published reports [ 13 , 16 , 24 – 26 ]. However, studies about prevalence rate of MetS are very few in Africa, with most of the studies originating from the southern and northern part of Africa [ 16 , 27 – 31 ].…”

Section: Discussionsupporting

confidence: 91%

“…Furthermore, the MetS prevalence observed in this study was in agreement with a range of prior reports published regionally and worldwide, although there is a considerable variation in criteria and methodology among the published reports [ 13 , 16 , 24 – 26 ]. However, studies about prevalence rate of MetS are very few in Africa, with most of the studies originating from the southern and northern part of Africa [ 16 , 27 – 31 ].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

Owusu-Ansah

Panyin

Obirikorang

et al. 2018

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

The study determined the prevalence of MetS in patients with schizophrenia at the Psychiatric Unit of the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. This comparative cross-sectional study recruited 348 schizophrenic patients comprising 236 antipsychotic-treated and 112 newly diagnosed treatment-naïve patients. The MetS prevalence was assessed based on World Health Organization (WHO), International Diabetes Federation (IDF), and the National Cholesterol Education Programme, Adult Treatment Panel III (NCEP ATP III) criteria. The overall prevalence of MetS was 14.1%, 20.4%, and 23.6% using NCEP ATP III, WHO, and IDF criteria, respectively, compared to 7.8%, 3.9%, and 2.2% reported in the general Ghanaian population. The prevalence was significantly higher among treated psychiatric patients compared to treatment-naïve group based on NCEP ATP III (17.8% versus 6.2%; p = 0.0001), WHO (26.2% versus 8.0%; p < 0.0001), and IDF (30.3% versus 10.0%; p < 0.0001). MetS was prevalent among patients on atypical antipsychotics compared to typical antipsychotics irrespective of the criteria used (i.e., 17.1% versus 11.1% for NCEP ATP III; 29.5% versus 25.9% for WHO; and 44.3% versus 18.5% for IDF). Using logistic regression model, obesity, raised fasting blood sugar, raised total cholesterol, and decreased high density lipoprotein were observed to be significant predictors of MetS (p<0.05).The study found high prevalence of MetS in Ghanaians with schizophrenia and higher prevalence rate of MetS associated with monotherapy. Regular monitoring of cardiometabolic parameters should be an important therapeutic objective in the management of these patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

Owusu-Ansah

Panyin

Obirikorang

et al. 2018

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

show abstract

“…Antipsychotic drugs vary considerably from one another in their effective dose, way of administration, pharmacokinetics, side effects and cost, all these factors effect choice of an S148 antipsychotic drug for a particular patient. Monitoring of patients for metabolic adverse effects is mandatory while prescribing second-generation antipsychotics to reduce their cardio-metabolic hazards 9,10 . However; the psychiatrists frequently use atypical antipsychotics in patients with schizophrenia and other psychiatrist illnesses without keen care of safety and hazard.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Two Widely Used Atypical Antipsychotics Olanzapine Versus Risperidone in Terms of Metabolic Outcomes

Hussain

Imtiaz

Amin

et al. 2021

PAFMJ

View full text Add to dashboard Cite

Objective: To compare the metabolic outcomes in psychiatric patients treated with Olanzapine and Risperidone. Study Design: Quasi experimental study. Place and Duration of Study: The study was conducted at Armed Forces Institute of Mental Health, Rawalpindi,from Aug 2016 to Jan 2017. Methodology: In this study 114 newly diagnosed psychiatric patients taking atypical anti-psychotics were selected and placed randomly into two groups i.e. group A (Olanzapine) andgroup B (Risperidone), 57 patients each. Patients of either gender, 20 to 60 years’ age, clinically diagnosed new cases having psychiatric illness using DSMV were selected consecutively. Baseline and six months’ end study data were collected and compared. Results: Total 14 out of 109 (5 patients lost follow up) patients developed metabolic syndrome. Among these 10(18.18%) were in group A while 4 (7.41%) were in group B. Patients receiving Olanzapine were 2.58 times moreprone to develop metabolic syndrome compared to the Risperidone receiving [RR= 2.58 {C.I. 0.85009, 7.62703}].Weight gain (p-value = 0.0048), increased Waist circumference (p-value = 0.00867) and elevated Blood Pressure (pvalue = 0.0563) were seen more significantly with use of Olanzapine. Conclusion: Olanzapine although associated with good efficacy but indeed with more serious and long-term side effects like impaired blood glucose tolerance, dyslipidemia and increase weight. Psychiatrist must screen and continuously monitor such patients.

show abstract

Metabolic syndrome associations with neurocognitive function in first-episode schizophrenia spectrum disorders

Luckhoff,

Suliman,

van den Heuvel

et al. 2024

Psychiatry Research Communications

View full text Add to dashboard Cite

Prevalence and risk factors of metabolic syndrome among drug-naive psychotic patients

Cited by 4 publications

References 19 publications

Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

Comparison of Two Widely Used Atypical Antipsychotics Olanzapine Versus Risperidone in Terms of Metabolic Outcomes

Metabolic syndrome associations with neurocognitive function in first-episode schizophrenia spectrum disorders

Contact Info

Product

Resources

About